Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 181
Filter
1.
Clin. transl. oncol. (Print) ; 23(8): 1620-1629, ago. 2021.
Article in English | IBECS | ID: ibc-222161

ABSTRACT

Background Although immunotherapy is thought to be a promising cancer treatment, most patients do not respond to immunotherapy. In this post hoc analysis of a phase 1/2 study, associations of programmed death ligand 1 (PD-L1), PD-L2, and HLA class I expressions with responses to dendritic cells (DCs)-based immunotherapy were investigated in patients with advanced sarcoma. Methods This study enrolled 35 patients with metastatic and/or recurrent sarcomas who underwent DC-based immunotherapy. The associations of PD-L1, PD-L2, and HLA class I expressions in tumor specimens, which were resected before immunotherapy, with immune responses (increases of IFN-γ and IL-12) and oncological outcomes were evaluated. Results Patients who were PD-L2 (+) showed lower increases of IFN-γ and IL-12 after DC-based immunotherapy than patients who were PD-L2 (−). The disease control (partial response or stable disease) rates of patients who were PD-L1 (+) and PD-L1 (−) were 0% and 22%, respectively. Disease control rates of patients who were PD-L2 (+) and PD-L2 (−) were 13% and 22%, respectively. Patients who were PD-L1 (+) tumors had significantly poorer overall survival compared with patients who were PD-L1 (−). No associations of HLA class I expression with the immune response or oncological outcomes were observed. Conclusions This study suggests that PD-L1 and PD-L2 are promising biomarkers of DC-based immunotherapy, and that addition of immune checkpoint inhibitors to DC-based immunotherapy may improve the outcomes of DC-based immunotherapy (AU)


Subject(s)
Humans , Male , Female , Adult , B7-H1 Antigen/metabolism , Histocompatibility Antigens Class I/metabolism , Antineoplastic Agents, Immunological , Sarcoma/therapy , Dendritic Cells , Biomarkers, Tumor , Sarcoma/immunology , Sarcoma/pathology , Treatment Outcome
2.
Clin Transl Oncol ; 23(8): 1620-1629, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33635466

ABSTRACT

BACKGROUND: Although immunotherapy is thought to be a promising cancer treatment, most patients do not respond to immunotherapy. In this post hoc analysis of a phase 1/2 study, associations of programmed death ligand 1 (PD-L1), PD-L2, and HLA class I expressions with responses to dendritic cells (DCs)-based immunotherapy were investigated in patients with advanced sarcoma. METHODS: This study enrolled 35 patients with metastatic and/or recurrent sarcomas who underwent DC-based immunotherapy. The associations of PD-L1, PD-L2, and HLA class I expressions in tumor specimens, which were resected before immunotherapy, with immune responses (increases of IFN-γ and IL-12) and oncological outcomes were evaluated. RESULTS: Patients who were PD-L2 (+) showed lower increases of IFN-γ and IL-12 after DC-based immunotherapy than patients who were PD-L2 (-). The disease control (partial response or stable disease) rates of patients who were PD-L1 (+) and PD-L1 (-) were 0% and 22%, respectively. Disease control rates of patients who were PD-L2 (+) and PD-L2 (-) were 13% and 22%, respectively. Patients who were PD-L1 (+) tumors had significantly poorer overall survival compared with patients who were PD-L1 (-). No associations of HLA class I expression with the immune response or oncological outcomes were observed. CONCLUSIONS: This study suggests that PD-L1 and PD-L2 are promising biomarkers of DC-based immunotherapy, and that addition of immune checkpoint inhibitors to DC-based immunotherapy may improve the outcomes of DC-based immunotherapy.


Subject(s)
B7-H1 Antigen/metabolism , Histocompatibility Antigens Class I/metabolism , Immunotherapy , Programmed Cell Death 1 Ligand 2 Protein/metabolism , Sarcoma/therapy , Adult , Biomarkers, Tumor/metabolism , Dendritic Cells , Female , Humans , Interferon-gamma/metabolism , Interleukin-12/metabolism , Male , Sarcoma/immunology , Sarcoma/mortality , Sarcoma/pathology , Treatment Outcome
3.
Eur J Surg Oncol ; 39(6): 655-61, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23523318

ABSTRACT

BACKGROUND: We evaluated the methylation patterns of histone H3 lysine 27 (H3K27), H3 lysine 36 (H3K36) and the expression of H3K27 methylase EZH2 in patients with colorectal carcinomas with metachronous liver metastasis to search for biomarkers identifying these patients. METHODS: Double 2-mm core tissue microarrays were made from 54 paraffin-embedded samples of primary colorectal adenocarcinomas and corresponding liver metastases and examined using an immunohistochemical analysis of dimethylation and trimethylation in H3K27, H3K36 and EZH2. Positive tumor cell staining for each histone modification (H-score) was used to classify patients into low- and high-staining groups, which were then examined to identify any correlations between the clinicopathological parameters and the clinical outcomes. RESULTS: The H-scores of H3K27me2 were lower in the liver metastases than in the corresponding primary tumors, while the H-scores of H3K36me2 were higher in the liver metastases than in the corresponding primary tumors (P < 0.001). H3K27me2 in the primary tumors correlated with tumor size (P = 0.016), H3K36me2 in the primary tumors correlated with histological type (P = 0.038), and H3K36me3 in the primary tumors correlated with lymph node metastasis (P = 0.017). In addition, lower levels of H3K27me2 in the primary tumors correlated with poorer survival rates (P = 0.039). The multivariate survival analysis showed that the H3K27me2 status is an independent prognostic factor for colorectal cancer patients (P = 0.047). CONCLUSIONS: Our findings suggest that the methylation level of H3K27me2 detected with immunohistochemistry may be an independent prognostic factor for metachronous liver metastasis of colorectal carcinomas.


Subject(s)
Adenocarcinoma/metabolism , Colorectal Neoplasms/metabolism , Histones/metabolism , Liver Neoplasms/metabolism , Neoplasms, Second Primary/metabolism , Polycomb Repressive Complex 2/metabolism , Adenocarcinoma/enzymology , Adenocarcinoma/genetics , Adenocarcinoma/secondary , Adult , Aged , Colorectal Neoplasms/enzymology , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , DNA Methylation , Enhancer of Zeste Homolog 2 Protein , Female , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Liver Neoplasms/enzymology , Liver Neoplasms/genetics , Liver Neoplasms/secondary , Lysine , Male , Methylation , Middle Aged , Multivariate Analysis , Neoplasms, Second Primary/enzymology , Neoplasms, Second Primary/genetics , Neoplasms, Second Primary/secondary , Prognosis , Retrospective Studies , Risk Factors , Tissue Array Analysis
4.
Eur J Surg Oncol ; 38(11): 1051-7, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22959167

ABSTRACT

BACKGROUND: To search for biomarkers identifying pancreatic cancer patients likely to benefit from adjuvant gemcitabine chemotherapy, we investigated the status of several histone modifications in pancreatic tumors and their relationship to clinicopathological features and outcomes. METHODS: Sixty one pancreatic cancer patients, primarily treated by surgical removal of tumors, were involved in the study. Thirty patients completed postoperative adjuvant gemcitabine, and in 31 it was discontinued. Tumor specimens were examined using immunohistochemistry for di- and tri-methylation of histone H3 lysine 4 (H3K4me2 and H3K4me3), dimethylation and acetylation of histone H3 lysine 9 (H3K9me2 and H3K9ac), and acetylation of histone H3 lysine 18 (H3K18ac). Positive tumor staining for each histone modification was used to classify patients into low- and high-staining groups, which were examined for relationships to clinicopathological features and clinical outcomes. RESULTS: High expression of H3K4me3 was related to the well and moderately differentiated tumor histological type (p = 0.012) and low expression of H3K4me2 was related to the presence of perineural invasion (p = 0.007). No cellular histone modifications were associated with overall or disease-free survival of patients as a whole. In the subgroup analyses, a low level of H3K4me2 was significantly associated with worse disease free survival in patients that completed adjuvant gemcitabine (p = 0.0239). Univariate and multivariate hazard models also indicated that a low level of H3K4me2 was a significant independent predictor of disease-free survival (p = 0.007). CONCLUSION: H3K4me2 was found to be a predictor of response to adjuvant gemcitabine in Asian patients with pancreatic cancer.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Deoxycytidine/analogs & derivatives , Histones/metabolism , Pancreatic Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Chemotherapy, Adjuvant , Deoxycytidine/therapeutic use , Disease-Free Survival , Female , Humans , Immunohistochemistry , Lysine/metabolism , Male , Methylation , Middle Aged , Pancreatic Neoplasms/metabolism , Gemcitabine
5.
Rev Sci Instrum ; 80(3): 033904, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19334931

ABSTRACT

This paper describes a novel method for the fabrication of a thin film deposited on an appropriate substrate having a continuous composition gradient. The composition gradient was achieved by a combination of pulsed laser ablation (PLA) of the target material with a very strong acceleration field generated on a moving disk rotating at a very high speed. The PLA process was used to produce a cloud of high-energy particles of the target material that will be deposited on a substrate placed on the rotating disk. After deposition, the particles will diffuse on the surface of the thin film under a strong acceleration field. The high energy of the particles and their diffusion on the substrate surface in a high-vacuum environment produces a macroscopic composition distribution in the thin film. We have constructed an experimental apparatus consisting of a vacuum chamber in which a circular disk made of titanium is driven by a high-frequency inductive motor. An acceleration field of up to 10,000 G can be generated by this apparatus. Functionally graded material thin films of FeSi(2) with a continuous concentration gradient were successfully fabricated by this method under a gravity field of 5400 G. A significant advantage of this method is that it allows us to fabricate graded thin films with a very smooth surface covered by few droplets.

6.
Transpl Infect Dis ; 9(1): 11-5, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17313465

ABSTRACT

Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age. We retrospectively reviewed medical records of 123 patients (median age of 55; range, 17-79) who received reduced-intensity cord blood transplantation (RI-CBT). Patients preemptively received reduced-dose foscarnet 30 mg/kg twice daily when CMV antigenemia exceeded 10/50,000. Sixty-three patients developed CMV antigenemia on a median of day 34, and 29 received foscarnet preemptively. The median level of CMV antigenemia at the initiation of foscarnet was 30. Median duration of foscarnet administration was 24 days. Adverse effects included electrolyte abnormalities (n=19), renal impairment (n=13), and skin eruption requiring discontinuation of foscarnet (n=1). Preemptive therapy of foscarnet was completed in 18 patients. Seven patients died during foscarnet use without developing CMV disease. The remaining 3 developed CMV enterocolitis 5, 14, and 17 days after initiation of foscarnet. All of them were successfully treated with ganciclovir or foscarnet. Reduced dose of foscarnet is beneficial to control CMV reactivation following RI-CBT; however, it has considerable toxicities in RI-CBT recipients with advanced age. Further studies are warranted to minimize toxicities and identify optimal dosages.


Subject(s)
Antiviral Agents/administration & dosage , Cord Blood Stem Cell Transplantation/adverse effects , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/prevention & control , Cytomegalovirus , Foscarnet/administration & dosage , Postoperative Complications , Adolescent , Adult , Aged , Antigens, Viral/blood , Cytomegalovirus/immunology , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/blood , Enterocolitis/drug therapy , Enterocolitis/etiology , Exanthema/chemically induced , Female , Ganciclovir/therapeutic use , Humans , Japan , Male , Middle Aged , Neoplasms/therapy , Renal Insufficiency/chemically induced , Retrospective Studies , Treatment Outcome , Water-Electrolyte Imbalance/chemically induced
7.
Bone Marrow Transplant ; 36(6): 517-23, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16025150

ABSTRACT

Thrombotic microangiopathy (TMA) is a significant complication after hematopoietic stem-cell transplantation (HSCT); however, there is little information on it following reduced-intensity cord blood transplantation (RI-CBT). We reviewed the medical records of 123 adult patients who received RI-CBT at Toranomon Hospital between January 2002 and August 2004. TMA was diagnosed in seven patients based on intestinal biopsy (n = 6) or autopsy results (n = 1). While these patients showed some clinical symptoms such as diarrhea and/or abdominal pain, mental status alterations or neurological disorders were not observed in any of them. Laboratory results were mostly normal at the onset of TMA; >2% fragmented erythrocytes (n = 1), <10 mg/dl haptoglobin (n = 1), and >200 IU/dl lactic dehydrogenase (LD) (n = 4). On endoscopic examination, TMA lesions, consisting of ulcers, erosions, and diffuse exfoliation, were distributed spottily from terminal ileum to rectum. Intestinal graft-versus-host disease (GVHD) and cytomegalovirus (CMV) colitis were confirmed in five and four patients, respectively. With therapeutic measures including supportive care (n = 4), fresh frozen plasma (n = 1), and a reduction of immunosuppressive agents (n = 1), TMA improved in four patients. The present study demonstrates that intestinal TMA is a significant complication after RI-CBT. Since conventional diagnostic criteria can overlook TMA, its diagnosis requires careful examination of the gastrointestinal tract using endoscopy with biopsy.


Subject(s)
Cord Blood Stem Cell Transplantation/adverse effects , Hemolytic-Uremic Syndrome/etiology , Intestinal Diseases/etiology , Purpura, Thrombotic Thrombocytopenic/etiology , Adolescent , Adult , Aged , Colitis/virology , Cord Blood Stem Cell Transplantation/methods , Cytomegalovirus Infections , Female , Graft vs Host Disease , Humans , Incidence , Intestinal Diseases/diagnosis , Intestinal Diseases/pathology , Male , Middle Aged , Retrospective Studies
9.
Bone Marrow Transplant ; 35(1): 91-7, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15516933

ABSTRACT

Allogeneic hematopoietic stem cell transplantation (allo-SCT) recipients are prone to infections. The incidences of mycobacterial infections after allo-SCT in several case series vary from less than 0.1-5.5%. However, no study has been published on tuberculosis following unrelated cord blood transplantation (UCBT). We retrospectively reviewed medical records of 113 adult patients with a median age of 54 years who underwent reduced-intensity UCBT (RI-UCBT) at Toranomon Hospital from March 2002 to May 2004. Mycobacterium tuberculosis infections were diagnosed in three patients (2.7%), of these two patients developed primary infection and one patient developed reactivation of latent tuberculosis. The interval between RI-UCBT and the diagnosis of tuberculosis was 34, 41 and 61 days. All the patients had disseminated disease at diagnosis. Histological examination showed the lack of granuloma in caseous necrosis. Combination antituberculous treatments showed limited efficacy, and two patients died immediately after diagnosis. M. tuberculosis caused life-threatening illness, rapidly progressing in RI-UCBT recipients. The lack of granuloma in caseous necrosis suggests the impaired T-cell function in early post transplant phase of RI-UCBT. We should consider M. tuberculosis in the differential diagnoses of fever of unknown source after RI-UCBT.


Subject(s)
Cord Blood Stem Cell Transplantation/adverse effects , Hematologic Diseases/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Mycobacterium Infections/etiology , Tuberculosis/etiology , Adolescent , Adult , Aged , Diagnosis, Differential , Female , Fetal Blood , Granuloma/metabolism , Humans , Male , Middle Aged , Mycobacterium tuberculosis , Necrosis , Remission Induction , Retrospective Studies , Time Factors , Tomography, X-Ray Computed , Tuberculosis/diagnosis
11.
Bone Marrow Transplant ; 33(7): 697-702, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14755317

ABSTRACT

To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received RIST in the Tokyo SCT consortium from January 2000 to October 2002. The preparative regimens were fludarabine-based (150-180 mg/m(2), n=18) or cladribine-based (0.77 mg/kg, n=2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatment-related mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived >100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35%. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0%, P=0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients.


Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Histocompatibility Testing , Transplantation Conditioning/methods , Vidarabine/analogs & derivatives , Adult , Aged , Antilymphocyte Serum/administration & dosage , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/methods , Bone Marrow Transplantation/mortality , Cladribine/administration & dosage , Feasibility Studies , Female , Graft vs Host Disease/drug therapy , Graft vs Host Disease/etiology , Graft vs Host Disease/prevention & control , Hematologic Diseases/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/mortality , Histocompatibility , Humans , Male , Middle Aged , Neoplasms/therapy , Retrospective Studies , Survival Analysis , Transplantation Conditioning/adverse effects , Transplantation Conditioning/mortality , Transplantation Immunology , Treatment Outcome , Vidarabine/administration & dosage , Whole-Body Irradiation
12.
Bone Marrow Transplant ; 32(11): 1089-95, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14625581

ABSTRACT

We reviewed medical records of 256 patients to investigate the frequency and characteristics of hemorrhagic cystitis (HC) associated with reduced-intensity stem cell transplantation (RIST) as opposed to conventional stem cell transplantation (CST); 137 patients underwent CST and 119 RIST. Diagnosis of HC was made based on two or more episodes of sterile, macroscopic hematuria with normal coagulation profiles, without any evidence of renal stones or genitourinary malignancy. Actuarial frequency of HC development in RIST group was 7.6% (9/119), which gave a cumulative annual incidence of 11.7%. In CST group, 13 of 137 patients (9.5%) developed HC, giving an estimated annual incidence of 9.7%. The probability of developing HC was similar between the two groups (P=0.77). The viral etiologies of HC, adenovirus (n=12) and BK virus (n=2), were documented in eight patients after RIST and in six after CST. HC was milder and of a shorter duration, with less blood transfusion requirements, in RIST group than in CST group. A multivariate analysis revealed that HC was associated with antiadenovirus antibody positivity in the recipients, total dose of busulfan, and chronic GVHD. Although HC following RIST is less severe than that following CST, it is still a significant problem.


Subject(s)
Cystitis/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Adenoviridae/immunology , Adolescent , Adult , Aged , Antibodies, Viral/blood , Busulfan/administration & dosage , Busulfan/toxicity , Child , Child, Preschool , Cystitis/chemically induced , Cystitis/virology , Dose-Response Relationship, Drug , Female , Graft vs Host Disease/complications , Hematopoietic Stem Cell Transplantation/methods , Hemorrhagic Disorders/chemically induced , Hemorrhagic Disorders/etiology , Hemorrhagic Disorders/virology , Humans , Incidence , Infant , Male , Middle Aged , Retrospective Studies , Risk Factors , Time Factors
14.
Bone Marrow Transplant ; 32(2): 131-7, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12838276

ABSTRACT

The possible advantage of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a graft-versus-lymphoma effect. We explored the feasibility and efficacy of allo-HSCT with reduced-intensity (RI) regimens in advanced malignant lymphoma (ML). A total of 20 patients with indolent (n=9) or aggressive lymphoma (n=11) received allo-HSCT with an RI regimen (RIST). The preparative regimen consisted of a combination of purine analog and alkylating agent with or without antithymocyte globulin. A total of 11 patients had chemorefractory disease, seven had chemosensitive relapsed disease and two had residual disease. All of the patients received G-CSF-mobilized blood stem cells from HLA-matched siblings. Of the 20 patients, 19 achieved engraftment with acceptable regimen-related toxicities. Seven patients developed grade II-IV acute GVHD and 15 developed chronic GVHD. Of the 15 patients with evaluable disease, 12 achieved a complete response. One died of invasive fusariosis, four subsequently died of GVHD complicated with fungal infection and one died of progressive disease. With a median follow-up of 358 days, the Kaplan-Meier estimates for 1-year overall and progression-free survival were both 70%. The high response rate with low relapse observed in this study suggests that RIST may be an effective alternative curative treatment for patients with advanced ML.


Subject(s)
Lymphoma/therapy , Peripheral Blood Stem Cell Transplantation/methods , Transplantation Conditioning/methods , Adult , Alkylating Agents/therapeutic use , Antilymphocyte Serum/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Feasibility Studies , Female , Humans , Lymphoma/complications , Lymphoma/mortality , Male , Middle Aged , Peripheral Blood Stem Cell Transplantation/adverse effects , Peripheral Blood Stem Cell Transplantation/mortality , Purines/therapeutic use , Remission Induction/methods , Salvage Therapy/methods , Survival Analysis , Transplantation Chimera , Transplantation Conditioning/adverse effects , Transplantation Conditioning/mortality , Transplantation, Homologous , Treatment Outcome
15.
Ann Hematol ; 81(7): 407-9, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12185516

ABSTRACT

A 23-year-old man with chronic myelocytic leukemia (CML) in the first chronic phase underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from his HLA-identical sibling. Pretransplant evaluations showed that he had a low risk of transplantation-related mortality and that the interval between the diagnosis of CML and PBSCT was only 6 months. However, he developed a variety of complications, including acute renal failure requiring hemodialysis, severe hepatic damage, hemorrhagic cystitis, and gastrointestinal hemorrhage leading to hypovolemic shock. Pathological examination of the colonic mucosa showed vascular endothelial damage and thrombotic lesions, leading to the diagnosis of thrombotic microangiopathy. Later, we found that he had the constitutional abnormality XYY. XYY syndrome is a frequent congenital abnormality, and mental disorders and congenital abnormalities of kidney and liver are common manifestations. Considering his clinical course, it was interesting that complications were severe in the organs which are frequently involved in cases of XYY syndrome. These organs may have poor function or poor reserves and may be more vulnerable to endothelial damage caused by high-dose cytotoxic chemotherapy. Patients with XYY syndrome might have a high risk of transplantation-related mortality.


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery , Peripheral Blood Stem Cell Transplantation/adverse effects , XYY Karyotype , Adult , Humans , Male , Microcirculation , Thrombosis/etiology , Transplantation, Homologous , XYY Karyotype/genetics
16.
Bone Marrow Transplant ; 30(3): 195-8, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12189539

ABSTRACT

A 27-year-old man with aplastic anemia and renal insufficiency requiring dialysis underwent allogeneic PBSCT. The preparative regimen consisted of melphalan, ATG and TLI. GVHD prophylaxis consisted of cyclosporine and prednisolone. He was dialyzed prior to administration of melphalan and at 24 and 72 h after it. Otherwise, the dialysis schedule was unchanged, at three times a week. Engraftment was rapid. Regimen-related toxicity was minimal. Pharmacokinetic parameters of melphalan were not significantly altered with its plasma half-life 1.5 h. Patients with renal failure can receive allogeneic HSCT, and a combination of melphalan, ATG and TLI may serve as an alternative to CY and ATG.


Subject(s)
Anemia, Aplastic/therapy , Peripheral Blood Stem Cell Transplantation , Renal Insufficiency/therapy , Adult , Anemia, Aplastic/complications , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/toxicity , Cross Infection/prevention & control , Graft Survival , Graft vs Host Disease/prevention & control , Humans , Lymphatic Irradiation , Male , Melphalan/administration & dosage , Melphalan/blood , Melphalan/pharmacokinetics , Peripheral Blood Stem Cell Transplantation/methods , Renal Dialysis , Renal Insufficiency/complications , Transplantation Conditioning/methods , Transplantation, Homologous
17.
Jpn J Clin Oncol ; 31(10): 514-6, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11696623

ABSTRACT

Multiple atypical adenomatous hyperplasia (AAH) of both lungs in a 72-year-old male, detected by computed tomography, is reported. The lesions of the right lung were resected for diagnosis via video-assisted thoracoscopic surgery (VATS). The resected specimen had 22 AAH lesions up to 10 mm in size. For nine of these lesions, the expressions of carcinoembryonic antigen (CEA), c-erbB-2 oncoprotein and p53 gene product were examined by immunohistochemistry and the loss of heterozygosity (LOH) on chromosomes was investigated by polymerase chain reaction analysis. These lesions showed a variety of expressions for CEA, c-erbB-2 and p53 oncoprotein. Three of the nine lesions showed LOH on chromosome 13q, although this was not exhibited in the largest one. These results indicate that each AAH in this case has independent genetic abnormalities and is multicentric.


Subject(s)
Adenomatosis, Pulmonary/diagnostic imaging , Biomarkers, Tumor/blood , Lung Neoplasms/diagnostic imaging , Adenomatosis, Pulmonary/genetics , Adenomatosis, Pulmonary/surgery , Aged , Carcinoembryonic Antigen/blood , Humans , Hyperplasia , Immunohistochemistry , Loss of Heterozygosity , Lung Neoplasms/genetics , Lung Neoplasms/surgery , Male , Receptor, ErbB-2/blood , Thoracic Surgery, Video-Assisted , Tomography, X-Ray Computed , Tumor Suppressor Protein p53/blood
18.
Leuk Lymphoma ; 42(4): 819-22, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11697515

ABSTRACT

We describe a patient who underwent successful BMT from her sibling for the treatment of adult T-cell leukemia/lymphoma. Pre-transplant examination of the donor revealed oligoclonal integration of HTLV-I proviruses within the germ line, and our concern was that clinical sequelae of HLTV-I infection might become evident in the setting of post-transplant immunosuppression. However, the patient has been in complete remission for 14 months after transplantation, and no clonality of HTLV-I provirus was detected in the peripheral blood cells using southern blotting analysis. Our experience supports the possibility of transplantation from HTLV-I positive donors.


Subject(s)
Bone Marrow Transplantation , HTLV-I Infections , Leukemia-Lymphoma, Adult T-Cell/therapy , Tissue Donors , Cell Division , Clone Cells/pathology , Clone Cells/virology , Female , HTLV-I Infections/transmission , Humans , Middle Aged , Remission Induction , T-Lymphocytes/pathology , T-Lymphocytes/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...